research on semaglutide Can Ozempic and Weight-Loss Drugs Treat Other Diseases? Semaglutide as a GLP-1 Agonist:

What Studies Have NOT Demonstrated in Humans Despite community claims, no controlled human trial has demonstrated: A specific body fat percentage reduction attributable to LR3 IGF-1 cycling A specific lean mass gain figure for the standard 10-day-on / 4-week-off pattern Cardiovascular safety endpoints across repeated cycles Long-term cancer-incidence data for cycled LR3 IGF-1 use Epidemiological data on chronically elevated endogenous IGF-1 has raised theoretical cancer concerns (Yoshida & Delafontaine, 2020), and that concern is one reason community protocols favor short, spaced cycles rather than continuous use

Continue reading Praluent vs Repatha: What's the difference

Remarkably, the combination of PHA, SE with AST showed the most prominent anti-inflammatory effects compared to any other group in this study

A.WeimarT.LilleyK